A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
about
Shepherding AKT and androgen receptor by Ack1 tyrosine kinaseReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersProstate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Therapeutic value of quinazoline-based compounds in prostate cancer.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.Overcoming drug resistance and treating advanced prostate cancerGenomic and epigenomic alterations in prostate cancer.Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation.Targeting the androgen receptor pathway in prostate cancer.Current management of prostate cancer: dilemmas and trialsMultitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerToxicity of targeted therapies in elderly patients.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.Docetaxel-based combination therapy for castration-resistant prostate cancer.Castration-resistant prostate cancer: targeted therapies.Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin.Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
P2860
Q24308859-1824886D-4D7E-44CD-B2BB-D2D7C0F0B970Q28082793-D19DA06F-B224-405D-8732-06D7E9A800BCQ30573685-2CC9E8FB-D832-44AF-ACDF-C7CE0B6069DBQ33416977-D479F480-AC3E-45DA-8AA3-9FFCAA650547Q33677975-BFE7AD21-39DF-408B-BBBA-0431538A734AQ33746225-069D5341-7A30-4E0E-B1EE-55BD027F51BAQ34985562-D1B983AB-1401-40D8-8558-6A6319D06EDAQ35269318-1DCA58F8-BFFC-45D3-9218-12BE32AC104AQ35829712-65A5A77F-7BA2-4D17-B334-8E28F1D5EB58Q36328812-B2F3C8FA-73FC-439E-9853-1AB01CF40CF4Q36374578-088D1D90-156E-4B91-AB53-42C79F466583Q36544282-724E0BF8-9F06-42C1-9EE2-E663B70E59FFQ36953028-B78FBB24-F6FB-44F5-8640-2D94FE53F389Q37102535-DF57D141-E64D-46D9-94C4-DA863799322DQ37127044-0856CCBD-EF15-4E80-B5B7-6C9E25355128Q37338263-A82BB449-47C2-4C57-A4C4-6DE9BC814ED1Q37575815-A6F84E61-1F64-4F20-8A4D-4FC26C685C5BQ37635634-00D9BD6A-D619-4D56-8D65-4A70B7E3D6E5Q37721016-3E40EC1B-E855-40E5-B49B-D5B93F097583Q37856646-8305C909-E740-42A2-9083-3CD30BC193C4Q37950948-8B4442F8-BF9A-42EB-A096-96C64B623276Q37968256-E42757B0-E0CB-4E05-9712-66D741C95557Q38262816-C0685237-479B-4545-9BBA-1A706DE8D080Q38750494-060F3E43-0AAD-4FEF-AFC7-FBC81A8ECD98Q39139802-A797B48F-4DF2-468C-8B80-7B55A2FF1AAAQ39466416-5954A966-7D6F-44C6-934A-E0350568D8B5Q39527913-5AAA22EC-5656-4998-ADC9-3DC40D1F7EDEQ39568883-5419AE0B-D80A-4A16-B312-C987E7FD4713Q50420907-4359F9B9-0A62-4176-939A-A41E2C84BD73Q50455684-EF5CBB9B-9399-4656-B496-A1101F0ED658
P2860
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase II trial of docetaxel ...... n-independent prostate cancer.
@ast
A phase II trial of docetaxel ...... n-independent prostate cancer.
@en
A phase II trial of docetaxel ...... n-independent prostate cancer.
@nl
type
label
A phase II trial of docetaxel ...... n-independent prostate cancer.
@ast
A phase II trial of docetaxel ...... n-independent prostate cancer.
@en
A phase II trial of docetaxel ...... n-independent prostate cancer.
@nl
prefLabel
A phase II trial of docetaxel ...... n-independent prostate cancer.
@ast
A phase II trial of docetaxel ...... n-independent prostate cancer.
@en
A phase II trial of docetaxel ...... n-independent prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
A phase II trial of docetaxel ...... n-independent prostate cancer.
@en
P2093
Allan Pantuck
Celestia Higano
David B Agus
Erica Green
Koo Nguyen
Olga Castellanos
P2860
P2888
P356
10.1186/1471-2407-7-142
P407
P577
2007-07-27T00:00:00Z
P5875
P6179
1024396194